Knight Therapeutics Inc. (TSX: GUD) announced that it has fully repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin, a strategic move to expand its pan-American pharmaceutical footprint. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, highlighting the company's financial discipline and operational strength.
The revolving credit facility remains available, providing borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions. This credit line continues to support Knight’s ongoing growth strategy across its pan-American pharmaceutical business. The repayment reduces debt and strengthens the company's balance sheet, positioning it for future acquisitions or investments.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM. The company’s shares trade on the TSX under the symbol GUD. For more information about the company, please visit www.knighttx.com.
This development is significant as it demonstrates Knight’s ability to generate sufficient cash flow to repay debt while maintaining access to capital for future growth. The Paladin acquisition was a key strategic move, and repaying the debt quickly indicates strong integration and financial performance. Investors may view this as a positive signal of management’s prudent financial management and the company's solid operational foundation.
The announcement was disseminated on behalf of Knight Therapeutics Inc. and may include paid advertising. For the full press release, visit https://ibn.fm/8eluB.
